1	Kinetics and durability of humoral responses to SARS-CoV-2 infection and vaccination
2	Komal Srivastava ^{1,2*} , Juan Manuel Carreño ^{1,2*} , Charles Gleason ^{1,2*} , Brian Monahan ^{1,2*} , Gagandeep
3	Singh ^{1,2} , Anass Abbad ^{1,2} , Johnstone Tcheou ^{1,2} , Ariel Raskin ^{1,2} , Giulio Kleiner ^{1,2} , Harm van
4	Bakel ^{6,1,7} , Emilia Mia Sordillo ³ , PARIS Study Group ^{1,2} , Florian Krammer ^{1,2,3*} , Viviana Simon ^{1,2,3,4,5*}
5	1-
6	¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
7 8	² Center for Vaccine Research and Pandemic Preparedness (C-VARPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA
9 10	³ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
11 12	⁴ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
13 14	⁵ The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
15 16	⁶ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
17	⁷ Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
18	
19	* Shared contributions
20	To whom correspondence should be addressed: viviana.simon@mssm.edu and
21	florian.krammer@mssm.edu
22	
23	PARIS Study Group (alphabetical order): Hala Alshammary, Angela A. Amoako Dalles Andre,
24	Mahmoud Awawda, Maria C Bermúdez-González, Katherine F. Beach, Dominika Bielak, Gianna Y.
25	Cai, Rachel L. Chernet, Christian Cognigni, Yuexing Chen, Lily Q. Eaker, Emily D. Ferreri, Daniel
26	L. Floda, Miriam Fried, Joshua Z. Hamburger, Denise Jurczyszak, Hyun Min Kang, Neko Lyttle,
27	Julia C. Matthews, Jacob Mauldin, Wanni A. Mendez, Jacob Mischka, Sara Morris, Lubbertus CF
28	Mulder, Ismail Nabeel, Jessica Nardulli, Annika Oostenink, Kayla T. Russo, Ashley-Beathrese
29	Salimbangon, Miti S. Saksena, Amber A. Shin, Levy A. Sominsky, Daniel Stadlbauer, Leeba
30	Sullivan, Morgan Van Kesteren, Temima Yellin, Ania Wajnberg
31	
32	Keywords: SARS-CoV-2 immunity, antibodies, durability, SARS-CoV-2 variants, model
33	
34	
35	

36

37 Abstract

38 We analyzed the kinetics and durability of the humoral responses to severe acute respiratory 39 syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination using >8,000 longitudinal 40 samples collected over a three-year period (April 2020 - April 2023) in the New York City 41 metropolitan area. Upon primary immunization, participants with pre-existing immunity mounted 42 higher antibody responses faster and achieved higher steady-state levels compared to naïve 43 individuals. Antibody durability was characterized by two phases: an initial rapid decay, followed by 44 a phase of stabilization with very slow decay resulting in an individual spike binding antibody 45 steady state. Booster vaccination equalized the differences in antibody levels between participants 46 with and without hybrid immunity, but the antibody titers reached decreased with each successive 47 antigen exposure. Break-through infections increased antibody titers to similar levels as an 48 additional vaccine dose in naïve individuals. Our study provides strong evidence for the fact that 49 SARS-CoV-2 antibody responses are long lasting, with an initial waning phase followed by a 50 stabilization phase.

51 INTRODUCTION

52 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 53 2019 sparked the global coronavirus disease 2019 (COVID-19) pandemic that is now in its fourth 54 year. Vaccines to mitigate the impact of the pandemic were developed at record speed and have saved millions of lives. However, the emergence of SARS-CoV-2 variants¹ and waning immunity² 55 have decreased the effectiveness of the vaccines against symptomatic disease³. These two 56 57 issues, emergence of antigenically distinct SARS-CoV-2 variants and waning immunity, are often 58 conflated and used interchangeably but represent two different phenomena⁴. Most vaccines used 59 in North America and Europe are based on lipid nanoparticles (LNP) containing messenger RNA 60 (mRNA) produced by Pfizer/BioNTech (BNT162b2) or Moderna (mRNA-1273), and the common perception now is that mRNA-based vaccine-induced immunity wanes quickly⁵. However, this 61 62 assumption is mostly based on data from short-term studies that include a very limited number of data points following peak responses^{2,5}. 63

64 In March of 2020, the densely populated New York metropolitan area was hit with an 65 exponential increase of severe SARS-CoV-2 infections resulting in a staggering number of fatalities and a severely overburdened health care system⁶⁻⁸. Due to shortages of personal 66 67 protective equipment, essential workers in the health care system were at high risk for infection. In 68 response to this crisis, we established (a) a specific and sensitive SARS-CoV-2 binding enzyme-69 linked immunosorbent assay (ELISA) to measure humoral immune responses⁹, and (b) an 70 observational longitudinal cohort of health care workers of the Mount Sinai Health System to 71 determine the kinetics of these humoral responses. This study, named Protection Associated with Rapid Immunity to SARS-CoV-2 (PARIS)¹⁰, aims to capture the dynamics of SARS-CoV-2 antibody 72 73 responses to both infection as well as vaccinations, to determine re-infection rates, and to assess 74 correlates of protection in the context of individual immune histories.

75 With over 8,000 longitudinal study visits across a single cohort during the first three years of 76 the pandemic, our investigation represents one of the most extensive and in-depth assessments of 77 the longevity of SARS-CoV-2 immune responses to date. Using this longitudinal cohort, we 78 determined the kinetics of antibody responses to spike protein after infections, during the primary 79 immunization series, during monovalent and bivalent booster vaccination as well as during 80 breakthrough infections. Our findings indicate that, in contrast to common perception, COVID-19 81 mRNA vaccination induces long-lasting antibody responses in humans. The PARIS study also 82 provides insights into the effect of booster vaccination and breakthrough infections on the stability 83 of antibody responses.

84 **Results**

85 STUDY DESIGN

PARIS (*Protection Associated with Rapid Immunity to SARS-CoV-2*) is an observational longitudinal study that enrolled 501 adults, mostly healthcare workers (**Table 1**) with or without preexisting SARS-CoV-2 immunity. The first participants were enrolled in April 2020 when NYC emerged as one of the very early epicenters of the pandemic in the United States. We have conducted over 8,000 study visits with data and biospecimen collection spanning a three-year period (April 2020 to March 2023).

92 Of the participants, 67% were female and 56% self-identified as white. The mean age at 93 study enrollment was 41 years (Table 1). At the first study visit, 62% of the participants had no 94 measurable SARS-CoV-2 spike binding antibodies (naive, seronegative). At each study visit we 95 collected data and biospecimen (e.g., blood, saliva). Study visits were scheduled at shorter 96 intervals (2-4 weeks) from study entry through week 8 after enrollment, but the intervals between 97 visits were extended (to approximately 4-8 weeks) for follow-up visits after week 8. Ad hoc study 98 visits were included at short intervals (e.g., weekly) after immune events such as vaccination or 99 infection. Serum samples were used to measure antibodies binding to the ancestral spike protein 100 using an established in-house method that was developed early in the pandemic⁹.

101 465 of 501 PARIS participants (93%) were vaccinated against SARS-CoV-2 using mRNA 102 vaccines: 342/465 received two doses of Pfizer BNT162b2 and 111/465 received two doses of 103 Moderna mRNA-1273. A small proportion of participants received one dose of the Johnson & 104 Johnson vaccine [Ad26.COV2.S], or two doses of the CoviShield[™] [AZD1222] vaccine as their 105 primary SARS-CoV-2 immunization regimen (Table 1). The number of vaccine doses administered 106 to a given PARIS participant ranged from two to six doses. Briefly, 366/465 (79%) of PARIS 107 participants who completed their primary immunizations subsequently elected to receive a third 108 vaccine dose ("booster"). Of these 366 participants, 97 (27%) received a second booster (4th 109 vaccine dose overall: 27/97 monovalent ancestral booster vaccine versus 70/97 bivalent ancestral/BA.5 vaccine). Of these 97 participants, 15 opted for a third booster (5th vaccine dose 110 overall). Of these 15 participants, one opted for a fourth booster (6th vaccine dose overall). Lastly, 111 112 14/27 participants with two monovalent boosters elected to get the bivalent booster.

113

114 ANTIBODY RESPONSES TO INFECTION AND PRIMARY IMMUNIZATION

38% of the study participants entered the PARIS study having detectable spike binding IgG
 antibodies, albeit at highly variable levels (Figure 1, area under the curve (AUC) range at baseline:

117 12.5 to 4,189). Infection-induced anti-spike antibodies showed relatively high stability over 118 approximately 10 months of pre-vaccine follow-up. A detailed analysis of this phase of the study 119 has been reported previously¹¹.

120 Vaccinations with mRNA vaccines were available to health care workers in Mid-December 2020 (December 15th, 2020, for Pfizer BNT162b2; December 28th, 2020, for Moderna mRNA-121 122 1273). In naïve individuals, the first dose of the mRNA vaccine induced no to relatively low levels of 123 antibodies (Suppl. Figure 2A) but the second vaccine dose, administered 16-31 days after the first 124 (Pfizer BNT162b2: median 21 days [range:16-30]; Moderna mRNA-1273: median 27 days [21-31], 125 increased titers to 5,936 (AUC, peak at 35 days post first dose, Figure 2A, Suppl. Figure 2). In 126 contrast, individuals with pre-existing immunity induced by infection reached peak titers faster, 127 approximately 10 days after the first dose and achieved significantly higher antibody titers (AUC 128 19,594, peak at 10 days post first dose (Figure 2A, Suppl. Figure 2). After completing the primary 129 immunization regimen, participants without pre-existing immunity had > 3-fold lower peak 130 responses compared to participants with pre-existing immunity (p<0.001).

131 During the approximately 400 day-long follow-up period, we found an initial steep five-fold 132 drop of antibody titers in vaccinated individuals with and without pre-existing immunity followed by 133 a stabilization phase (Figure 2A). Based on a simple rolling geometric mean, post-vaccine data 134 was observed to have two rough "phases" with different rates of decay (Figure 3A). This 135 observation resembled a bi-phasic decay that is well-approximated by a two-component threeparameter one-phase exponential decay model framework, prompting us to explore the kinetics of 136 137 the antibody response in more detail. We fitted a nonlinear mixed-effects (NLME) model to 138 describe the antibody dynamics from two weeks up to one year after the completion of the primary 139 vaccination series. The same model was also fit to antibody dynamics after the third vaccine dose. 140 Specifically, our model has two components: a rapid-decay component with a half-life measured in 141 weeks to months (e.g., antibodies produced by the plasmablast response), and a steady-state 142 component to capture convergence to stable titers during prolonged follow-up (e.g., antibodies 143 produced by long-lived plasma cells) (Suppl. Figure 3A).

NLME models were fit using the NLMixed procedure in SAS to account for variable longitudinal sampling between participants. A per-participant random effect for each component accounts for the significant variability in both antibody response magnitude and kinetics. Fixed effects due to demographic parameters and vaccine type were fit as multiplicative shifts in the expected geometric mean area under the curve (AUC) across the entire time course. Datasets were stratified by immune status prior to vaccination, with models fit independently to each group. Results for the final models including demographic factors are reported, with independent

151 models fitted for post-vaccine and post-boost antibody dynamics as well as for participants with 152 ("hybrid immunity") and without ("naïve") pre-vaccine SARS-CoV-2 infection (**Suppl. Table 1**).

153 The PARIS NLME model fits closely the observed antibody dynamics post-vaccination, 154 irrespective of prior infection status (Figure 3A, 3B). It also provides the means for a personalized 155 two-component immunity score accounting for an individual's SARS-CoV-2 immune history 156 reflecting both the magnitude of the peak response and the stability of that response (Suppl. 157 Figure 3). These two phases with distinct half-lives distinguish the PARIS model from commonly 158 available models that only consider exponential decay in binding antibodies after vaccination. 159 When comparing our two-phase decay model with a simple exponential decay model, we noted 160 that the latter overestimates the rate of decay in months 6 to 12 post-vaccination in our cohort 161 (Suppl. Figure 3B).

162 For the post-vaccine model (Figure 3A), the initial antibody levels measured at 14 days 163 after the second dose are 6,100 AUC in the naïve group (blue) and 17,000 AUC in the hybrid 164 immunity group (2.8-fold higher, in orange). This "peak" response is composed of two components 165 in each case. In the naïve group, the short-lived component has a magnitude of 5,700 AUC (95% 166 Confidence Interval [CI]: 5,200-6,400) with a half-life of 29.6 days (CI: 28.1-31.2) and the stable 167 component has a magnitude of 330 AUC (CI: 290-370). In the hybrid immunity group, the short-168 lived component has a magnitude of 15,000 AUC (CI: 13,000-18,000) with a half-life of 30.7 days 169 (CI: 28.4-33.5) and the stable component has a magnitude of 1,800 AUC (CI: 1,500-2,100). 170 Because of the larger difference in the stable component, the gap between the hybrid immunity 171 group and the naïve group increases to 4.8-fold at 180 days and 5.4-fold at 360 days after 172 completion of the primary immunization regimen, respectively. Six months after vaccination, the 173 predicted geometric mean antibody titer (GMT) was 445 AUC in the vaccine-only immunity group 174 corresponding to an 18.6-fold reduction relative to the peak antibody levels. In the hybrid immunity 175 group, the predicted GMT was 2,142 corresponding to a 10.7-fold reduction relative to the peak 176 antibody levels. Reductions in antibody levels over the next six months. At 12 months post-177 vaccination, the predicted GMT was 329 in the vaccine-only immunity group corresponding to only 178 a 1.35-fold reduction relative to antibody levels six months after vaccination. In the hybrid immunity 179 group, the predicted GMT was 1,783 AUC a year after the initial immunization corresponding to a 180 1.2-fold reduction relative to antibody levels at six months post-vaccination. Thus, although the 181 kinetics of decay in the stable plateau phase are comparable between the two groups, the 182 predicted antibody titer levels for each group differed by more than four-fold (e.g., AUC 329 versus 183 AUC 1,783).

184 In addition to examining broad patterns in antibody kinetics, we specifically quantified the 185 impact of vaccine type as well as demographic factors including gender, age, race, and ethnicity. 186 Effects were modeled as a constant multiplicative increase or decrease in GMT over the entire time 187 course. Of these, only age and vaccine type were statistically significant at the p < 0.05 level in any 188 group. The effect of vaccine type is illustrated in **Figure 3D** for the post-vaccine model. There is a 189 statistically significant effect in the naïve group, with a 1.43-fold increase in antibody levels (CI: 190 1.20-1.70) in the Moderna mRNA-1273 vaccine recipients compared to the Pfizer BNT162b2 191 recipients. There was no statistically significant impact of vaccine type noted in the hybrid immunity 192 group. The effect of age was modest but nonetheless significant in the naïve group: each decade 193 of additional age lived corresponded to a 1.17-fold decrease in antibodies (CI: 1.041-1.187) 194 (Suppl. Table 1). In the hybrid immunity group, there was no statistically significant effect.

In summary, based on our data and modeling, antibody titers achieved a steady state seven to nine months after the primary vaccination series. Stable titers were higher for individuals with hybrid immunity as compared naïve vaccinees suggesting induction of long-lived serum antibody titers even after the primary vaccination series. In addition, vaccine type and age had a modest but measurable influence on antibody titer levels in participants without hybrid immunity.

200

201 ANTIBODY RESPONSES TO BOOSTER IMMUNIZATIONS

202 Third dose booster vaccination were authorized for health care workers in September 2021 203 (September 22nd, 2021, for Pfizer BNT162b2 and October 20th, 2021, for Moderna mRNA-1273). 204 Booster vaccination resulted in 27-fold increases in peak spike antibody responses in previously 205 naive individuals (Figure 2B). In contrast, hybrid immune individuals displayed only a 4-fold 206 increase due to their higher baseline. Four weeks after booster vaccination, the peak titers were 207 similar between previously naïve participants (mean AUC: 10,162) and those with hybrid immunity 208 (mean AUC: 8,001, Figure 2B). This stands in stark contrast to the humoral immune responses 209 mounted upon the primary series (Figure 1, Figure 2A, Suppl. Fig. 2B). The third vaccine dose 210 seemed to act as an 'equalizer' lifting the antibody titers of participants with vaccine-only immunity 211 for the first time in our longitudinal study to the level of those with infection- and vaccine-induced 212 immunity.

Antibody kinetics post-boost were different compared to kinetics after the primary series (**Figure 3B**). The initial waning of antibodies was slower, and titers stabilized at similar levels to those of the hybrid immune group post-primary vaccination. Importantly, titers settled at comparable levels for both previously naïve and participants with hybrid immunity and stabilized

again after approximately seven to nine months. Interestingly, although they stabilized at similar
 levels, peak levels post boost were moderately but significantly lower than in the hybrid immune
 group post primary vaccination series.

220 The fourth vaccine dose did boost serum antibody levels, albeit to a much lower fold-221 increase compared to prior vaccine doses (vaccine-only 3.9-fold, hybrid immune 4.8-fold) (Figure 222 **2C**). The peak antibody titers after the second booster vaccine were comparable to the peak titers 223 achieved after the first booster vaccination. Antibody waning kinetics were also very similar to the kinetics observed after administration of the 3rd vaccine dose (Figure 1, Figure 2B, Suppl. Fig.2). 224 225 For individuals receiving a third/fourth booster dose (fifth or sixth vaccine dose overall), the data 226 was too sparse for an in-depth analysis, but antibody titers were generally within the same range observed post-3rd and post-4th vaccine doses (Figure 1). 227

228 We next used our model for the analysis of post boost antibody kinetics. For the post-boost 229 model, antibody levels at 14 days after third dose are 9,500 AUC in the naïve group and 7,400 230 AUC in the hybrid immunity group (Figure 3B). In the naïve group, the short-lived component had 231 a magnitude of 7,500 AUC (CI: 6,500-8,700) with a half-life of 44 days (CI: 39-50) and the stable 232 component has a magnitude of 2,000 AUC (CI: 1500-2500). In the hybrid immunity group, the 233 short-lived component has a magnitude of 5400 UC (CI: 4,300-6,800) with a half-life of 73 days 234 (CI: 60-93) and the stable component has a magnitude of 2,000 AUC (CI: 1,400-2,700). Predicted 235 geometric mean antibody levels 180 days after the beginning of the modeling period (14 days post-236 boost) are 0.22-fold peak antibody levels in the non-hybrid immunity group and 0.38-fold peak 237 antibody levels in the hybrid immunity group. The rate of decay slows over the next six months, 238 with predicted antibody levels at day 360 of the modeled period are 0.79-fold antibody levels at day 239 180 in the naïve group and 0.70-fold day 180 antibody levels in the hybrid immunity group. Despite 240 this difference in shape, the geometric mean magnitude of the antibody response is similar across 241 both groups throughout the entire time course studied, with fold-change between groups with and 242 without hybrid immunity ranging from 0.72 to 1.22 and no detectable difference in the magnitudes 243 of the stable component of the model. Because of this, antibody kinetics after boost are well 244 approximated by a single model trained on a combined dataset disregarding prior infection status 245 (Figure 3B).

We next compared antibody kinetics after the first booster immunization to those mounted after the primary vaccination (**Figure 3C**). In the model, peak antibody levels after boost are between those for the naïve and hybrid immunity groups post-primary vaccination, and the stable component of the response post-boost is slightly higher in the hybrid immunity group suggesting slower decay. Of note, in the post-boost dataset, the effect due to primary vaccine type follows a

pattern like that observed after the primary immunization. Participants without hybrid immunity who received the Moderna mRNA-1273 vaccine for their primary series show a 1.41-fold increase relative to Pfizer recipients (CI: 1.10-1.82). The hybrid immunity group shows no statistically significant difference nor trend due to primary vaccine type. Taken together, our data indicate that booster vaccine doses increase the level at which long term serum antibody responses stabilize.

256

257 IMMUNE RESPONSES UPON BREAKTHROUGH INFECTIONS

While during the early phase of the pandemic, re-infections were rare, breakthrough infections increase with the emergence of variants of concern, especially the Omicron variant. Viral variants of concern started to circulate in the NYC metropolitan area in early 2021 (**Figure 4A**). In our study, we identified breakthrough infections based on participant self-reporting (rapid antigen tests or PCR testing at external facilities), nucleic acid amplification tests and/or an increase in antibody titers (e.g., >4-fold).

264 A total of 225 SARS-CoV-2 infections were recorded among participants over the duration 265 of the PARIS study, with most new infections (214/225) occurring after immunization (at least one 266 vaccine dose administered). We documented three infections after the first vaccine dose and 37 267 infections after the second vaccine dose but before the booster vaccination (Figure 4B). There 268 were 174 breakthrough infections identified in participants who had received at least one booster 269 vaccine dose. The bulk of breakthrough infections were observed after December 20, 2021, when 270 Omicron BA.1 started to spread widely in our community (192/214 new infections). At that point in 271 time. 299 PARIS participants had received a vaccine dose within the prior six months (10/289 272 second dose of the primary immunization series, 288/289 a booster vaccine dose). 55/299 273 participants who received a vaccine dose within six months prior to the Omicron wave, experienced 274 a breakthrough infection between December 2021 and February 2022. Nine infections occurred at 275 least 14 days after the participant received a bivalent booster. Of note, one person had three 276 consecutive infections with Omicron variants. Interestingly, before highly antigenically distinct 277 Omicron variants started to circulate in the NYC metropolitan area beginning around mid-278 December 2021 (Figure 4A), most breakthrough infections occurred in vaccinated individuals who 279 were previously naïve, and none occurred in the hybrid immunity group (Figure 4C, left panel). 280 After the emergence of the different Omicron lineages, this picture changed, and breakthrough 281 infections also became more common in hybrid immune individuals (Figure 4C, right panel), but 282 hybrid immunity continued to have a protective effect as compared to non-hybrid immunity 283 (p=0.00029, log rank test).

284 We next explored whether breakthrough infections differed from booster vaccination with 285 respect to the increased antibody magnitude. We compared the data for 176 breakthrough 286 infections (at least 14 days after primary vaccination) to the effect observed after receiving an 287 additional vaccine dose (Figure 4D). To start, we compared the effect of a booster dose after the 288 primary immunization series (VVV) in participants who had no recorded infection to the change in 289 antibodies in participants who experienced a breakthrough infection after the primary immunization 290 series (VVI). Breakthrough infection in participants who had only had vaccine induced antibodies 291 was the third antigen encounter and increased antibody titers by more than 30-fold, in a manner 292 comparable to an mRNA vaccine booster dose. If the breakthrough infection was the fourth antigen 293 encounter, the fold induction was lower (due to a higher baseline) resulting in an approximately four to five-fold increase which was comparable to a 4th vaccine dose. For the fourth antigen 294 295 encounter, in the case of a participant whose breakthrough infection was not their first infection and 296 who initially had hybrid immunity (IVVI), however, saw a relatively lower fold change in antibody 297 responses as opposed to participants with hybrid immunity who received a booster dose (IVVV). 298 This difference may be due to the hybrid immunity limiting virus replication during breakthrough 299 infections, leading to less immune stimulation. A similar observation was made when the 300 breakthrough infection as opposed to booster dose was the fifth exposure in participants with 301 hybrid immunity. Especially in formerly naïve individuals, one could argue that breakthrough 302 infections, their first infections, are equivalent to vaccine booster doses in terms of antibody 303 response, while in individuals with hybrid immunity the vaccine has a better effect on boosting 304 systemic antibodies when compared to a second infection.

305

306 **REACTOGENICITY DURING PRIMARY VACCINATION SERIES AND BOOSTER DOSES**

307 In addition to immunogenicity, we analyzed the reactogenicity profiles associated with the 308 different vaccine doses in study participants with and without immunity prior to the primary 309 immunizations. After each vaccine dose, participants were provided a survey to provide self-310 reported side effects experienced. This analysis builds on preliminary data published in early 311 2021¹² which reported that participants with pre-existing immunity experience more systemic side 312 effects after the first vaccine dose compared to naïve participants. We now have data not only on 313 the reactogenicity of the second and third vaccine doses but also longitudinal data on how side 314 effects changed at an individual level.

We collected information regarding local (injection site: pain, erythema, induration, lymphadenopathy) and systemic (e.g., chills, fatigue, fever, headache, arthralgia, myalgia

317 nausea/emesis, pharyngitis) side effects using a survey that allowed participants to self-report the 318 signs and symptoms experienced after each of the first three vaccine doses. 391 PARIS 319 participants provided survey responses regarding symptoms experienced after the 1st vaccine 320 dose, 333 participants provided survey responses to the second dose, and 254 participants 321 responded to the side effects survey after a booster dose. From all survey responses received, we 322 selected the subset of 228 participants (69% female, 70% naïve at primary vaccination) who 323 submitted surveys after each of the first, second and third vaccine doses. Of note, 69% of these 324 respondents received three doses of Pfizer BNT162b2, 21% three doses of Moderna mRNA-1273, 325 and 11% had a mix of vaccine types. Participants without three mRNA vaccine doses were 326 excluded. The distribution of vaccine types was broadly similar across participants with differing 327 immune histories (Suppl. Table 3).

328 Overall, the vaccines were well tolerated with most participant experiencing mild to 329 moderate side effects. Of the participants who reported severe side effects, none required medical 330 attention. 60-72% of the participants who completed all three surveys reported at least one 331 symptom (Dose 1: 60%, Dose 2: 72%, Dose 3: 67%). Across all vaccine doses and independent of 332 infection history, injection site pain is the top reported local side effect and fatigue is the top 333 reported systemic side effect. 11/160 naïve participants and 5/68 participants with hybrid immunity 334 recorded a breakthrough infection prior to the booster dose. Participants with hybrid immunity 335 experienced overall more side effects (Figure 5) although the difference in frequency relative to 336 naïve participants became smaller with each additional vaccination. After the first dose, both local 337 and systemic side effects were more common in participants with pre-existing immunity compared 338 to naïve participants (Figure 5). After the second dose naïve participants reported a higher 339 incidence of systemic side effects while the frequency of local injection site symptoms remained 340 relatively unchanged. The booster vaccination resulted in less painful injection site reactions in the 341 participants with hybrid immunity (Dose 1/2: 63% vs. Dose 3: 49%) while there was no such 342 difference in the vaccine only immunity group (Dose 2: 52% vs Dose 3: 53%). Both groups also 343 reported lymphadenopathy (e.g., axillary) to occur more frequently (7-11%) while fatigue remained 344 unchanged (43-44%). The incidence of chills jumped from 6% to 28% in the naïve group while 345 participants with hybrid immunity only experienced a two-fold increase (19% to 32%) upon booster 346 vaccination. Suppl. Table 4 provides a summary of the frequency of side effects. When analyzing 347 the data, age had no observable trend for the incidence or severity of reported vaccine 348 reactogenicity. Female participants reported more side effects in most categories when compared 349 to male participants, but this could also be a bias from the side effects respondents' group as most 350 participants are female. In the naïve participant subgroup, Moderna mRNA-1273 vaccinees

experienced more chills, nausea, arthralgia, fever, headache, erythema and induration at the injection site after the second and third dose of the vaccine compared to Pfizer vaccinees. The median duration between 2nd and 3rd vaccine doses was 272 days (range: 155-400).

354 To better capture how vaccine reactogenicity changes between the three vaccine doses 355 and visualize symptom clusters, we performed Unweighted Pair Group Method with Arithmetic 356 Mean (UPGMA) clustering based on Jaccard distance with optimal leaf ordering (Figure 5). This 357 ordering showed that, while overall frequencies of side effects appeared comparable between 358 Dose 2 and 3, this does not hold true at the individual participant level. Indeed, some participants 359 with vaccine induced immunity experienced little or no symptoms after the second dose but 360 reported several systemic side effects after the third dose while others had far fewer side effects 361 after the booster vaccination compared to the second dose.

Taken together, these real-world data indicate that pre-existing immunity modulates the reactogenicity with additional SARS-CoV-2 vaccine doses resulting in more pronounced side effects. Booster vaccine doses produced slightly fewer systemic side effects relative to the second vaccine dose in naïve participants while the opposite is true for those with hybrid immunity.

366 **Discussion**

The PARIS study¹⁰ aimed to investigate the durability of immune responses mounted to SARS-CoV-2 infection and vaccination. Indeed, the SARS-CoV-2 pandemic provided unprecedented challenges but also opportunities to address fundamental questions in human immunology. A large proportion of the human population was exposed — for the first time and within a very limited time window of the pandemic — to a new respiratory viral pathogen and to a series of sequential immunizations that included an antigen to which the whole population was naive.

374 We used our extensive longitudinal antibody data with frequent sampling to address several 375 important open questions about SARS-CoV-2 antibody-based immunity. It is often assumed that 376 immunity after vaccination with mRNA vaccines wanes quickly. In some cases, this is based on the observation that vaccine effectiveness decreases over time². However, declining vaccination 377 378 effectiveness is impacted not just by waning immune responses, but also by virus evolution¹³. In 379 other cases, the observation window is limited to the peak response and a brief period, thereafter, 380 producing a linear decay model that does not accurately reflect B-cell biology. Finally, many 381 studies analyze receptor binding domain-focused neutralizing antibodies only but ignore the large 382 number of other epitopes present on the spike protein. Our study design allows us to follow 383 individuals longitudinally from the onset of the pandemic, through primary immunization series and 384 now after booster immunizations providing an invaluable opportunity to comprehensively analyze 385 long-term kinetics of antibody-based immunity (Figure 1). We found that anti-spike antibody 386 kinetics after the primary immunization series follow a pattern that would be expected from basic B-387 cell biology. After primary vaccination, serum antibodies produced by plasmablasts reach a high 388 peak¹⁴. Plasmablast responses are the first line of defense when it comes to B-cells¹⁴. These cells 389 proliferate quickly, circulate in the periphery, and produce large amounts of antibodies - but typically disappear within two weeks^{15,16}. The antibodies they produce have a longer half-life (e.g., 390 391 IgG1 has a half-life of approximately four weeks¹⁷), but eventually also wane over the period of 392 weeks to months. This is consistent with the 28-to-34-day half-life of the short-lived component of 393 our PARIS model following the primary vaccination series. However, serum antibody responses 394 then stabilized after the initial few months. The more stable long-term serum antibody response is 395 likely produced by long-lived plasma cells which have in the meantime migrated from lymph nodes 396 into the bone marrow¹⁸. Again, the observations in our cohort basically follow textbook B-cell 397 biology. Interestingly, waning kinetics were slower after the booster doses and the level at which 398 titers stabilized became higher after each booster dose. We noted a clear "ceiling" effect with 399 respect to the overall peak antibody titers reached. While initial titers after the primary vaccination

400 series in previously infected individuals could reach almost 20,000 AUC, overall, the titers in 401 general seemed to peak at approximately 10,000 AUC. This ceiling seemed to slowly become 402 lower with repeated exposures and booster doses (**Figure 2**).

403 A key contribution of our study is the development of a robust model suitable for dissecting 404 the biological factors contributing to the durability of SARS-CoV-2 immune responses (Figure 3). 405 Leveraging our extensive longitudinal antibody data, we could identify patterns and associations 406 that shed light on the mechanisms underpinning long-term antibody protection. Our model allows 407 us to interrogate the determinants of antibody dynamics, including prior SARS-CoV-2 infection and 408 vaccine type as well as age. We found that individuals with initial infections followed by vaccination 409 had antibody decay kinetics similar to individuals who were naïve before the primary vaccination 410 series, however their peak titers were higher¹², and so was the titer at which their long-term serum 411 antibodies eventually settled. Interestingly, the booster dose acted as an equalizer, bringing the 412 serum antibody to similar levels in the group who was initially infected and the group that was 413 initially naïve. Other factors that influenced antibody titers, including long-term stable titers, were 414 age and vaccine type. As observed in other studies that stated superiority of Moderna mRNA-1273 over Pfizer BNT162b2 in terms of induced immune responses or protection^{19,20}, we saw that the 415 416 Moderna mRNA-1273 vaccine induced approximately 1.3-fold higher titers than the Pfizer 417 BNT162b2 vaccine, although differences were only significant in initially naïve individuals.

418 Our study also allowed us to determine infection rates in our cohort. We found that during 419 the pre-Omicron era very few breakthrough infections occurred and only in the previously naïve 420 group (Figure 4). During this time not a single breakthrough infection was detected in the hybrid 421 immune group over the course of 11 months. This changed significantly during the Omicron era 422 when the majority of our participants experienced breakthrough infections over the course of 18 423 months. This observation makes sense since Omicron has a strong escape phenotype and its 424 spike mutations undermine neutralizing antibodies induced by the ancestral or earlier variant 425 spikes¹. However, a notable protective effect remained in the hybrid immune group as compared to 426 initially naïve individuals (Figure 4C). We also assessed the immune responses to breakthrough 427 infections. When comparing the number of antigen exposures, we found that a breakthrough 428 infection after the primary vaccination series in previously naïve individuals induced antibody titers 429 comparable a third dose of vaccine (booster dose). We found a similar pattern for the fourth exposure (4th vaccine dose versus breakthrough infection after the 3rd vaccine dose). This suggests 430 431 that these initial breakthrough infections in vaccinated but previously naïve individuals do in fact act 432 similarly to a booster dose in terms of inducing antibody responses. The picture changed in 433 individuals who had an initial infection followed by two or three vaccinations. When comparing

breakthrough infection versus one additional vaccination in those highly exposed individuals we saw that vaccination still robustly boosted serum antibody titers but breakthrough infection did not, at least not as robustly as vaccination. We speculate that virus replication in these individuals was highly restricted due to their strong pre-existing immunity and that therefore the presence of less antigen leads to a lower induction of immunity.

439 Our longitudinal study setting also allowed us to investigate vaccine reactogenicity as it was 440 experienced after the first, second and third vaccine dose in a longitudinal manner at individual 441 participant level. These data are of great relevance since reactogenicity can increase vaccine 442 hesitancy and reduce uptake. In PARIS, SARS-CoV-2 mRNA vaccines were generally well 443 tolerated with mild to modest side effects occurring in two thirds of the vaccinees. As reported by 444 us and others^{12,21}, both local and systemic side effects were more common in individuals with 445 hybrid immunity (Figure 5). Our participant level analysis of vaccine reactogenicity reveal the 446 landscape of reactogenicity with several symptom clusters being apparent in the participant group 447 with no infection prior to vaccination. In future studies, we plan on analyzing whether certain 448 pattern of vaccine side effects predict the level of immunogenicity. These real-world data on side 449 effects associated with sequential vaccine doses is important to provide guidance for individuals 450 concerned regarding future immunizations.

451 Our study has several limitations. We were unable to analyze mucosal immune responses 452 which are especially interesting during breakthrough infections. We and other have previously 453 shown that secretory IgA antibodies are not induced or boosted by mRNA vaccination in 454 individuals who were previously naïve but that titers increase in hybrid immune individuals after their first vaccination^{22,23}. We plan, therefore, to conduct similar studies at additional time points in 455 456 our cohort in the future. Additionally, because our purpose was to analyze serum antibody kinetics, 457 the current study did not measure neutralizing antibody responses since binding antibodies contain 458 all antibodies to the spike and not just antibodies to certain neutralizing epitopes. Similarly, the 459 current study focused on antibodies to the full-length spike rather than RBD. However, since we have observed differential antibody kinetics for spike and RBD²⁴ (which is part of the spike), we 460 461 plan to measure RBD antibodies in the future. We plan to assess antibody avidity in our longitudinal cohort using different methods as previously described²⁵. Of note, binding antibodies 462 463 have been tied to protection from severe COVID-19 outcomes in the absence of neutralizing 464 antibodies in a recent study²⁶. Finally, the current study examines reactivity to ancestral spike, and not to later variant spikes or nucleoprotein. Assays utilizing the ancestral spike also detect 465 466 antibodies induced by variant breakthrough infection and existing bivalent vaccines. Indeed, it has

been shown that no to little specific antibodies are generated to new spikes and most of the response is cross-reactive^{27,28} in a manner consistent with 'backboosting²⁹.

In summary, we show that antibody responses to SARS-CoV-2 mRNA vaccination follow a classical biphasic decay with a rapid waning phase initially followed by a transition into a stabilization phase after 7-9 months. We also show that hybrid immunity showed better protection against breakthrough infection in both the pre-Omicron but also the post-Omicron era and we show that breakthrough infections in vaccinated, previously naïve individuals have an effect like a booster dose. These data suggest that COVID-19 mRNA vaccination does induce long lasting spike-specific antibodies consistent with B-cell biology.

476 **ACKNOWLEDGEMENTS**

477 We thank all the participants of our longitudinal PARIS study for their generous and continued 478 support of our COVID-19 research programs.

- This work was funded in part by the Centers of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014), by the Collaborative Influenza Vaccine Innovation Centers (CIVICs contract # 75N93019C00051), by philanthropic donations and by institutional funds including the Mount Sinai Center for Vaccine Research and Pandemic Preparedness.
- This effort was also in part supported by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91021F00001 via 21X092F1 Mod 01. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of
- 489 trade names, commercial products or organizations imply endorsement by the U.S. Government.
- 490

491 **CONFLICT OF INTEREST STATEMENT**

492 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 493 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-494 inventor. Dr. Viviana Simon is also listed on the SARS-CoV-2 serological assays patent. Mount 495 Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian 496 Krammer has consulted for Curevac, Merck and Pfizer, and is currently consulting for 3rd Rock 497 Ventures, GSK, Gritstone and Avimex and he is a co-founder and scientific advisory board 498 member of CastleVax. The Krammer laboratory is also collaborating with Pfizer on animal models 499 of SARS-CoV-2.

- 500
- 501
- 001
- 502
- 503
- 504
- 505
- 506

507 **References**

- 5081Carreño, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2509Omicron. Nature (2021). https://doi.org:10.1038/s41586-022-04399-5
- 5102Menegale, F. et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A511Systematic Review and Meta-analysis. JAMA Netw Open 6, e2310650 (2023).512https://doi.org:10.1001/jamanetworkopen.2023.10650
- 3 Zaeck, L. M., GeurtsvanKessel, C. H. & de Vries, R. D. COVID-19 vaccine effectiveness
 and evolving variants: understanding the immunological footprint. *Lancet Respir Med* 11,
 395-396 (2023). <u>https://doi.org:10.1016/S2213-2600(23)00140-6</u>
- 516 4 DeGrace, M. M. *et al.* Defining the risk of SARS-CoV-2 variants on immune protection. 517 *Nature* **605**, 640-652 (2022). <u>https://doi.org:10.1038/s41586-022-04690-5</u>
- 518 5 Feikin, D. R. *et al.* Duration of effectiveness of vaccines against SARS-CoV-2 infection and 519 COVID-19 disease: results of a systematic review and meta-regression. *Lancet* **399**, 924-520 944 (2022). <u>https://doi.org:10.1016/S0140-6736(22)00152-0</u>
- 521 6 Gonzalez-Reiche, A. S. *et al.* Introductions and early spread of SARS-CoV-2 in the New 522 York City area. *Science* **369**, 297-301 (2020). <u>https://doi.org:10.1126/science.abc1917</u>
- Wajnberg, A. *et al.* Humoral response and PCR positivity in patients with COVID-19 in the
 New York City region, USA: an observational study. *Lancet Microbe* 1, e283-e289 (2020).
 https://doi.org:10.1016/s2666-5247(20)30120-8
- 5268Stadlbauer, D. et al. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York527City. Nature **590**, 146-150 (2021). https://doi.org/10.1038/s41586-020-2912-6
- 528
 9
 Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat

 529
 Med 26, 1033-1036 (2020). https://doi.org/10.1038/s41591-020-0913-5
- 530 10 Simon, V. *et al.* PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2. *mSphere*531 7, e0017922 (2022). <u>https://doi.org:10.1128/msphere.00179-22</u>
- Kubale, J. *et al.* SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from
 Reinfection with Antigenically Similar SARS-CoV-2 Variants. *mBio* 13, e0178422 (2022).
 <u>https://doi.org:10.1128/mbio.01784-22</u>
- 535 12 Krammer, F. et al. Antibody Responses in Seropositive Persons after a Single Dose of 536 SARS-CoV-2 mRNA Vaccine. Ν Enal J Med 384. 1372-1374 (2021). 537 https://doi.org:10.1056/NEJMc2101667
- 53813Krammer, F. The role of vaccines in the COVID-19 pandemic: what have we learned?539Semin Immunopathol (2023). https://doi.org:10.1007/s00281-023-00996-2
- 54014Akkaya, M., Kwak, K. & Pierce, S. K. B cell memory: building two walls of protection against541pathogens. Nat Rev Immunol 20, 229-238 (2020). https://doi.org/10.1038/s41577-019-5420244-2
- 543 15 Wrammert, J. *et al.* Rapid cloning of high-affinity human monoclonal antibodies against 544 influenza virus. *Nature* **453**, 667-671 (2008). <u>https://doi.org:10.1038/nature06890</u>
- 545 16 Ellebedy, A. H. *et al.* Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. *Nat Immunol* **17**, 1226-1234 (2016).
 547 https://doi.org:10.1038/ni.3533
- 54817Mankarious, S. *et al.* The half-lives of IgG subclasses and specific antibodies in patients549with primary immunodeficiency who are receiving intravenously administered550immunoglobulin. J Lab Clin Med 112, 634-640 (1988).


- 55118Turner, J. S. et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in
humans. Nature 595, 421-425 (2021). https://doi.org/10.1038/s41586-021-03647-4
- 553 Ioannou, G. N., Locke, E. R., Green, P. K. & Berry, K. Comparison of Moderna versus 19 554 Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. 555 Veterans Affairs healthcare system. EClinicalMedicine 45, 101326 (2022). 556 https://doi.org:10.1016/j.eclinm.2022.101326
- Bajema, K. L. *et al.* Comparative Effectiveness and Antibody Responses to Moderna and
 Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans Five Veterans Affairs
 Medical Centers, United States, February 1-September 30, 2021. *MMWR Morb Mortal Wkly Rep* **70**, 1700-1705 (2021). <u>https://doi.org:10.15585/mmwr.mm7049a2</u>
- Atmar, R. L. *et al.* Homologous and Heterologous Covid-19 Booster Vaccinations. *N Engl J Med* 386, 1046-1057 (2022). <u>https://doi.org:10.1056/NEJMoa2116414</u>
- 56322Sano, K. et al. SARS-CoV-2 vaccination induces mucosal antibody responses in previously564infected individuals. Nat Commun 13, 5135 (2022). https://doi.org/10.1038/s41467-022-56532389-8
- 56623Sheikh-Mohamed, S. et al. Systemic and mucosal IgA responses are variably induced in
response to SARS-CoV-2 mRNA vaccination and are associated with protection against
subsequent infection. Mucosal Immunol **15**, 799-808 (2022).569https://doi.org:10.1038/s41385-022-00511-0
- 57024Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to571NTD, RBD, and S2. Cell184, 3936-3948.e3910 (2021).572https://doi.org:10.1016/j.cell.2021.06.005
- 573 25 Singh, G. *et al.* Binding and avidity signatures of polyclonal sera from individuals with 574 different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron 575 breakthrough infections. *J Infect Dis* (2023). <u>https://doi.org:10.1093/infdis/jiad116</u>
- 576 26 Vikström, L. et al. Vaccine-induced correlate of protection against fatal COVID-19 in older 577 and frail adults during waves of neutralization-resistant variants of concern: an 578 observational study. Lancet Reg Health Eur 30, 100646 (2023). 579 https://doi.org:10.1016/j.lanepe.2023.100646
- 58027Alsoussi, W. B. *et al.* SARS-CoV-2 Omicron boosting induces de novo B cell response in
humans. *Nature* (2023). https://doi.org:10.1038/s41586-023-06025-4
- 582 28 Carreño, J. M., Singh, G., Simon, V., Krammer, F. & group, P. s. Bivalent COVID-19
 583 booster vaccines and the absence of BA.5-specific antibodies. *Lancet Microbe* 4, e569
 584 (2023). <u>https://doi.org:10.1016/S2666-5247(23)00118-0</u>
- 585 29 Fonville, J. M. *et al.* Antibody landscapes after influenza virus infection or vaccination. 586 *Science* **346**, 996-1000 (2014). <u>https://doi.org:10.1126/science.1256427</u>
- 58730Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J588Med (2020). https://doi.org/10.1056/NEJMoa2034577
- 58931Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J590Med (2020). https://doi.org:10.1056/NEJMoa2035389
- 59132Stadlbauer, D. et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a592Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol 57, e100593(2020). https://doi.org/10.1002/cpmc.100
- 594

595 Table 1: Demographics and Immune histories in PARIS

Seropositivity pre-vaccine	Yes	No	Total		
	N=183	N=313	N=496		
Age					
mean – avg (std)	42 (11.7)	40 (11.6)	41 (11.6)		
range	21 - 77	22 - 74	21-77		
Gender - N (%)					
Female	118 (64%)	216 (69%)	334 (67%)		
Male	61 (33%)	88 (29%)	149 (30%)		
missing/other	4 (<1%)	9 (2%)	13 (3%)		
Ancestry - N (%)					
African American	15 (8%)	16 (5%)	31(6%)		
Asian	21(11%)	50 (16%)	71 (14%)		
White	104 (57%)	174 (56%)	278 (56%)		
missing/other	43 (24%)	73 (23%)	116 (24%)		
Ethnicity - N (%)		· · ·			
Hispanic	34 (19%)	51(16%)	85 (17%)		
Non-Hispanic	131 (72%)	218 (70%)	349 (70%)		
Missing/Other	18 (10%)	44 (14%)	62 (13%)		
Primary Vaccine Series	()		(/		
Moderna	35 (19%)	76 (24%)	111 (22%)		
Pfizer	127 (69%)	215 (69%)	342 (69%)		
Not Received	15 (8%)	20 (6%)	35 (7%)		
Other	5 (1%)	0 (0%)	5 (1%)		
Unknown	1 (<1%)	2 (<1%)	38 (8%)		
Vaccine Dose 3 (%)	-()	- ()	()		
Moderna	29 (16%)	67 (21%)	96 (19%)		
Pfizer	89 (49%)	174 (56%)	263 (53%)		
Not Received	64 (35%)	69 (22%)	133 (27%)		
Other	0 (0%)	1 (<1%)	1 (<1%)		
Unknown	1 (<1%)	2 (<1%)	3 (<1%)		
Vaccine Dose 4 (%)	1 (12/0)	2 (12/0)	3 (11/0)		
Moderna	1(<1%)	3 (1%)	4 (1%)		
Moderna Bivalent	3 (2%)	9 (3%)	12 (2%)		
Pfizer	5 (3%)	16 (5%)	21 (4%)		
Pfizer Bivalent	16 (9%)	38 (12%)	54 (11%)		
Bivalent Unspecified	1 (<1%)	3 (1%)	4 (1%)		
Unknown	1 (<1%)	1 (<1%)	2 (<1%)		
Not Received	156 (86%)	243 (78%)	399 (81%)		
Vaccine Dose 5					
Moderna Bivalent	0 (0%)	1(<1%)	1 (<1%)		
Pfizer Bivalent	5 (3%)	9 (3%)	14 (3%)		
Not Received	303 (97%)	178 (97%)	481 (97%)		
SARS-CoV-2 infections - N (%)	505 (5770)		-01(3770)		
	27 (15%)	151 (50%)	6 (50%)		
never	27 (15%) 109 (60%)	129 (42%)	6 (50%)		
Once Twice	45 (25%)	• •	0 (0%)		
		20 (7%)			
Thrice	2(1%)	1(<1%)	0 (0%)		

b description - N (%)			
Clinician	52 (28%)	99 (32%)	151 (30%)
PA/Nursing	37 (20%)	84 (26%)	121 (24%)
PhD/Trainee	19 (10%)	47 (15%)	66 (13%)
Social worker	6 (2%)	2 (<1%)	8 (2%)
Family Member	11 (6%)	3 (1%)	14 (3%)
Midwife	2 (1%)	3 (1%)	5 (1%)
Other	52 (28%)	65 (20%)	117 (24%)
Missing	4 (2%)	10(3%)	14 (3%)

599 Figure 1: Longitudinal SARS-CoV-2 spike binding antibody levels in 496 PARIS participants 600 over three years.





601

A: Each dot represents a distinct study visit at which spike binding antibody levels were measured. Samples are colored by prior vaccination status (2,091 samples pre-vaccination, 3,180 samples post-primary immunization [Dose 1, Dose 2], 2,364 samples post-Dose 3, 110 samples postmonovalent Dose 4, 240 samples post-bivalent dose 4, and 56 samples post-bivalent Dose 5).

606 Each SARS-CoV-2 antibody titer measurement (AUC, area under the curve) is anchored on the 607 Monday of the corresponding week. A small amount of normally distributed noise has been added 608 to the log2-transformed data (σ =0.1), with >95% of transformed values within 15% of the original 609 value to preserve participants' confidentiality.

610 **B, C**: SARS-CoV-2 infections (**B**) and vaccinations (**C**) events are depicted on the same timeline as 611 the antibody values. Three participants received their primary immunization as part of the Pfizer 612 vaccine trials. The vaccination event colors in the ribbon graph correspond to colors of points after 613 the respective event in the antibody scatterplot shown in Panel **A**.





615

616 Longitudinal spike binding antibodies measurements (N=4,620) for PARIS participants with 617 (orange) or without (blue) pre-existing SARS-CoV-2 immunity.


A: Longitudinal antibody follow-up post-vaccination for 179 participants with no prior SARS-CoV-2 infection (blue, 1,671 samples) and 111 participants with a pre-vaccine SARS-CoV-2 infection (orange, 1,083 samples). The right panel has matched pre- and post-vaccine timepoints for 150 previously naïve participants and 92 participants with hybrid immunity.

B: Longitudinal antibody follow-up pre- and post-third dose for participants with (83 participants, 585 samples) and without (160 participants, 1106 samples) prior SARS-CoV-2 infection. The right panel has matched pre- and post-third dose timepoints for 64 participants with prior infection and 126 participants without hybrid immunity.

626 **C**: Longitudinal antibody follow-up before and after the fourth vaccine dose is shown for 15 627 participants with SARS-CoV-2 infection prior to fourth dose (67 samples) and 26 participants 628 without hybrid immunity (108 samples). The right panel has matched pre- and post-fourth dose 629 timepoints for 13 participants with prior infection and 21 participants without hybrid immunity.

630

631 Timepoints post-breakthrough infection were excluded from the analysis. Pre-vaccination 632 timepoints were collected within 10 weeks prior to vaccination while peak post-vaccine timepoints 633 were 1-5 weeks after administration of the vaccine dose (the second dose, in the case of the 634 primary series). The increase in spike-binding antibodies post-vaccination was statistically 635 significant for all recipients (p < 0.0001, Wilcoxon signed rank). Peak antibody levels post-primary 636 vaccination were approximately 3-fold higher in the hybrid immunity group (p < 0.0001, Mann-637 Whitney U) compared to the vaccine-only immunity group. After third dose, peak antibody levels 638 were modestly elevated in the vaccination-only immunity group compared to those in the hybrid 639 immunity group (p = 0.023, Mann-Whitney U). Peak antibody levels post-dose 4 are comparable 640 across hybrid immunity and vaccination-only groups (no statistically significant difference, Mann-641 Whitney U).





644 **A**: We generated independent model predictions for the longitudinal post-vaccination antibody 645 levels in 359 participants with (orange dashed line, 126 participants, 850 samples) and without


646 (blue dashed line, 233 participants, 1,443 samples) SARS-CoV-2 infection prior to primary 647 immunization. The rolling 49-day geometric means for each group is shown as solid lines.

648 **B**: We fitted the same model to the longitudinal post-boost antibody levels of 223 participants (80 649 participants with hybrid immunity, 482 samples; 143 vaccination-only participants, 844 samples). 650 The rolling 49-day geometric means for each group is shown as solid lines.

651 **C**: The model predictions for the dynamics predicted by the post-vaccine model stratified by 652 infection status shown in panel A to a combined post-boost model in dark pink (223 participants, 653 1,326 samples).

D: The impact of vaccine type on antibody levels, with the fixed effect due to vaccine type separating model predictions for Pfizer recipients (dark blue and dark red dashed lines) and those for Moderna recipients (purple and red dotted lines). 95% confidence intervals of the fixed effect size are represented by the shaded area. Timepoints after breakthrough infections were excluded from the analysis. 95% confidence intervals are based on a T distribution with standard deviations calculated as part of the model fitting procedure. The vaccine type has a statistically significant effect in participants with no SARS-CoV-2 infection prior to vaccination (67% increase, p < 0.001).

661 **Figure 4: Frequency and impact of breakthrough infections**



662 **A**: The changing SARS-CoV-2 variant landscape in NYC is depicted for the period spanning 663 January 2021 to April 2023.


664 **B**: The number of breakthrough infections in vaccinated PARIS participants is shown by calendar 665 month (2021-2023). The number of vaccine doses that participants with breakthrough infections 666 received prior to infection are identified by the different colors.

667 **C**: The frequency of breakthrough infections changed after the emergence of Omicron variants in 668 Mid-December 2021. Participants with hybrid immunity were only experiencing breakthrough 669 infections with antigenically diverse Omicron variants (right panel). The differences between 670 vaccinated participants with and without hybrid immunity before (left) and after (right) the 671 appearance of Omicron variants is captured by Kaplan-Meier plots.

672 D: The impact of infection and vaccination on spike-binding antibody levels are shown. Vaccination 673 events are shown in blue and orange, with infection events shown in light blue and red. 674 Participants are categorized by number of prior exposures and SARS-CoV-2 infection status prior 675 to initial immunization. Second breakthrough infections are excluded. Third dose (dark blue, 676 n=126) is compared to post-vaccine breakthrough (light blue, n=12). Fourth dose (dark blue, n=21) 677 is paired with the breakthrough post-third dose (light blue, n=54). Third dose in previously infected 678 participants (orange, n=64) is paired with breakthrough re-infection post-vaccine (red, n=5). Finally, 679 antibody titers mounted in response to the fourth dose in previously infected participants (orange, 680 n=13) are compared those mounted after breakthrough re-infections after the third dose (red. 681 n=17).

682 Statistical comparisons within groups (Wilcoxon signed rank test) and fold-change in geometric 683 means are reported below each group. Statistically significant differences in post-exposure 684 antibodies at the p < 0.05 level (Mann-Whitney U test) are reported above.

685 Fig. 5: Reactogenicity reported after sequential SARS-CoV-2 accination (Dose 1, 2 and 3)



A, B: Each line represents the post vaccine side effects reported by the same participant. Data
 shown is based on 684 surveys completed by 228 participants (160 initially naïve, [70%, Panel A]
 and 68 with hybrid immunity, [30%, Panel B]) after the first, second and third vaccine dose. The

order of the symptoms depicted are divided into side effects at the local injection site (pain [1],
erythema [2], induration [3], lymphadenopathy [4], grey bands) and systemic in nature (fatigue [5],
headache [6], myalgia [7], chills [8], arthralgia [9], Fever [10], nausea/emesis [11], pharyngitis [12],
dark grey background).

Participants are split into groups based on pre-vaccine infection status and ordered by UPGMA clustering based on the Jaccard metric with optimal leaf ordering (trees shown on the left, colored clusters contain all nodes at distance less than 0.7). The presence of a symptom is indicated by a light blue bar. Bar plots for the overall frequency of each symptom are shown above the longitudinal data for each group. Vaccine type, boost type, infection status, and gender for each participant are annotated on the right.

699 TABLE OF CONTENT FOR THE SUPPLEMENTAL ONLINE MATERIALS 700 701 • ONLINE METHODS 702 703 • SUPPLEMENTAL TABLES \$4 to \$2

- 703 SUPPLEMENTAL TABLES S1 TO S3
- 704
- 705 SUPPLEMENTAL FIGURES S1 TO S4

706 **ONLINE METHODS**

Study Information: In Spring 2020, most of New York City was shut down except for essential personnel needed to fight the SARS-CoV-2 pandemic. Personal Protective Equipment was in high demand and needed to be distributed to essential workers providing high risk services. Health care workers performing a wide array of different jobs (e.g., from housekeeping, students, nurses to medical doctors) fell into this category.

The observational longitudinal PARIS Study (Protection Associated with Rapid Immune response to SARS-CoV-2) enrolled adult individuals who worked at the Mount Sinai Health System (MSHS) in New York City in April 2020. Adult family members of MSHS employees were also eligible for participation. The study protocol IRB-20-03374 / STUDY-20-00442 was approved by the Institutional Review Board of the Mount Sinai Hospital. All study participants signed written consent forms prior to providing data or biospecimen.

718 In the first two months of the study, participants were asked to provide saliva samples 719 weekly and to provide a blood sample every two weeks. After the two-month study visit, 720 participants returned monthly for a period of one year, thereafter study visit frequency varied 721 between one and two months. Nasopharyngeal or ante-near swabs were collected when 722 participants reported symptoms suggestive of a respiratory infection. Ad hoc study visits were 723 performed in these situations as well as after vaccination. If participants reported testing positive 724 for a viral respiratory infection, details about the diagnostic test performed, symptom onset and 725 disease severity were collected.

A total of 501 health care workers were enrolled in PARIS between April 2020 and August 2021. Prior to the SARS-CoV-2 vaccine rollout in December of 2020 412/501 participants had been enrolled. Based on serological status at baseline prior to vaccination, 38% of participants had SARS-CoV-2 spike binding IgG antibodies above the limit of detection of an in-house ELISA test. One single participant reported a SARS-CoV-2 infection prior to enrollment into the study but was seronegative at baseline.

732 Of the 501 participants enrolled, one (0.2%) has received four mRNA booster doses (total 733 vaccine doses: 6), 13 (2.6%) have received three mRNA booster doses (total vaccine doses: 5), 83 734 (16.6%) have received two mRNA booster doses (total vaccine doses: 4) and 269 (53.7%) 735 received one booster vaccine dose. 465 participants (93% of the total cohort) have been 736 vaccinated with the remainder of the participants having withdrawn or being lost to follow up since 737 immunization became mandatory for health care workers. Indeed, 36 participants withdrew from 738 the study and their vaccination status is unknown. Of the 465 participants who were vaccinated, 99 739 (21.3%) elected not to receive any booster vaccine dose. Over the three years of the PARIS study, 740 we have documented over 8,000 study visits collecting blood, saliva and/or nasal swabs.

741

742 Vaccine reactogenicity: Qualitative survey data capturing general health questions, exposures, 743 and changes to perceived risk to SARS-CoV-2 infection were captured monthly using a custom 744 build REDCap database. When participants received a SARS-CoV-2 vaccination, a survey to 745 collected information about side effects was sent out after the 1st and 2nd dose in the primary 746 immunization series as well as after the 1st booster vaccine dose.

After vaccination, surveys were sent to participants to provide data on side effects experienced after dose 1, 2 and 3. The questions for the survey were designed to capture diversity of possible effects broken into two categories: systemic effects and local injection site effects. The symptoms recorded (**Suppl. Table 2**) included side effects reported in publications from Pfizer and Moderna about their respective vaccines^{30,31}.

Dates by which vaccines became available to health care workers were as follows: Pfizer BioNTech: 12/15/2020 (initial) and 09/22/2021 (booster); Moderna: 12/28/2022 (initial), 10/20/21 (booster). Bivalent boosters (both Pfizer/BioNTech, Moderna) were distributed starting September 2022. Three participants received vaccine in the Pfizer Phase 3 vaccine trial.

756 The surveys for the first two doses were released early in 2021 and the booster survey was 757 launched in the fall of 2021. 245 participants completed all three surveys. Participants who did not 758 receive mRNA vaccination as their primary immunization or booster dose were excluded from the 759 analysis as well as participants with known immunomodulatory comorbidities leaving a total 760 complete survey response from 228 participants. For each indicated side effect, branching logic 761 questions were designed to ask about the duration of the side effect and perceived severity. For 762 fever and nausea/vomiting, guantitative ranges were asked. For fever, we asked about the highest 763 temperature known. For nausea/vomiting we asked about the number of times a day the 764 participant felt ill and vomited. The other side effects, if indicated as severe, had follow-up 765 questions to ask if medical care was required. None of the participants who reported a severe side 766 effect required hospitalization for treatment. All survey data was captured using REDCap 767 database system. Severity scoring was tabulated in a REDCap report output (not reported = 0, mild 768 = 1, moderate = 2, severe = 3) per effect per vaccine dose. The dataset for all three doses was 769 combined and subgroups based on infection history pre-vaccine, vaccine type, and gender were 770 created. Percent totals of reported incidence and severity were calculated per subgroup and then 771 compared to understand differences within the PARIS cohorts and observe trends between groups 772 across doses.

773

Enzyme-linked immunosorbent assay (ELISA): Antibody titers were measured using a two-step
 well-established ELISA method^{9,32} in which serum samples are screened at a single dilution (1:50)

776 for IgG against the recombinant receptor binding domain (RBD) of the spike protein from SARS-777 CoV-2 (Wuhan-Hu-1), followed by detection of antibodies against the full-length spike protein (also 778 Wuhan-Hu-1). In the first step, serum samples were screened in a high-throughput assay using the 779 recombinant RBD protein. In brief, 96-well microtitre plates (Thermo Fisher) were coated with 50 µl 780 recombinant RBD protein at a concentration of 2 µg/ml overnight at 4 °C. The next day, the plates 781 were washed three times with phosphate-buffered saline (PBS: Gibco) supplemented with 0.1% 782 Tween-20 (PBS-T; Fisher Scientific) using an automatic plate washer (BioTek). The plates were 783 blocked with 200 µl blocking solution consisting of PBS-T with 3% (w/v) milk powder (American 784 Bio) and incubated for 1 h at room temperature. Serum samples were heated at 56 °C for 1 h 785 before use to reduce the risk from any potential residual virus in the serum. The blocking solution 786 was taken off the plates and 100 µl of the serum samples diluted 1:50 in PBS-T containing 1% 787 (w/v) milk powder was added to the respective wells of the microtitre plates. After 2 h, the plates 788 were washed three times with PBS-T and 50 µl anti-human IgG (Fab-specific) horseradish 789 peroxidase antibody (produced in goat; Sigma, A0293) diluted 1:3,000 in PBS-T containing 1% 790 milk powder was added to all wells and incubated for 1 h at room temperature. The microtitre 791 plates were washed three times with PBS-T and 100 µl SigmaFast o-phenylenediamine 792 dihydrochloride (Sigma) was added to all wells. The reaction was stopped after 10 min with 50 µl 793 per well 3 M hydrochloric acid (Thermo Fisher) and the plates were read at a wavelength of 490 794 nm with a plate reader (BioTek). Serum samples that exceeded an optical density at 490 nm 795 (OD490) cut-off value of 0.15 were categorized as presumptive positive and were tested in a 796 second step in confirmatory ELISAs using the full-length, recombinant spike protein. To perform 797 the confirmatory ELISAs, the plates were coated and blocked as described above except full-798 length spike protein at a concentration of 2 µg/ml was added to the plates. After 1 h, the blocking 799 solution was removed, presumptive positive serum samples that were serially diluted (from 800 1:80/1:100 to 204,800) in 1% milk prepared in PBS-T were added and the plates were incubated 801 for 2 h at room temperature. The remainder of the assay was performed as described above. The 802 cut-off value was set to an OD_{490} value of 0.15 and true-positive samples were defined as samples 803 that exceeded an OD₄₉₀ value of 0.15 at a 1:80/1:100 serum dilution. The end-point titer was 804 calculated and defined as the last dilution before the signal dropped below an OD_{490} of 0.15. The 805 area under the curve (AUC) values were calculated and plotted using Prism 9 software 806 (GraphPad). AUC values >10 were plotted as above the limited of detection in the figures included 807 in this manuscript.

808

809 **SARS-CoV-2 variants:** Genomic data on the viral variants circulating within the New York City 810 metropolitan area were obtained through the New York City Department of Health and Mental

811 Hygiene (DOHMH) web portal. The DOHMH maintains a publicly available database updated 812 regularly since the beginning of the pandemic. SARS-CoV-2 variant tracking within the database 813 begins on January 1st, 2021, and was updated weekly until May 18th, 2023 (when the COVID-19) 814 emergency was declared over in the US). Data on specific viral variants was only available for 815 cases sequenced by and/or shared with the NYC DOHMH. Sequences were not available for all 816 the SARS-CoV-2 positive test cases reported to DOHMH. Certain variants within the NYC data 817 were collapsed into single categories due to the limited size of variant. The following variants were 818 combined: XBB and XBB 1.5; BQ1 and BQ 1.1, Omicron BF.7, BA.4 and BA.4.6; B.1.427 and 819 B.1.429 (Epsilon), and finally the B.1.526 lineages with and without E484K (lota).

820

821 Statistical Analysis: Statistical testing for paired samples was done using the Wilcoxon signed 822 rank test, with unpaired samples compared using the Mann-Whitney U test. The protectiveness of 823 hybrid immunity was evaluated using a log rank test. UPGMA clustering for Figure 5 and all 824 statistical tests were run using Scipy (version 1.11.1) in Python 3.9.15. Curve fitting for 825 Supplemental Figure 3 was done using the statsmodels package (version 0.13.2). All figures 826 were rendered using Matplotlib (3.7.1) and Seaborn (0.12.2). The antibody kinetic model was fit 827 using the NLMixed procedure in SAS9.4, using the trust region optimization technique and the 828 adaptive gaussian guadrature integration method, assuming a normal distribution for the random 829 effects and the dependent variable.

830

831 Non-Linear Mixed models for spike binding antibodies: Data were selected for the post-832 vaccine model under the following criteria: Timepoints with a discrepancy between the results 833 generated by the research grade SARS-CoV-2 spike-binding ELISA and the Kantaro spike-binding 834 assay performed in the CLIA certified Pathology laboratories of the Mount Sinai Hospital in the top 835 or bottom percentile over the entire dataset were excluded. Participants who did not receive two 836 doses of an mRNA vaccine as well as participants with unknown SARS-CoV-2 infection status prior 837 to immunization were also excluded. Similarly, data from participants without at least two valid 838 timepoints 14 days post-dose 2 were excluded. Samples obtained after subsequent vaccine doses 839 or breakthrough infections were censored.

Data were selected for the post-boost model using the following criteria: Participants excluded from the post-vaccine model dataset were also excluded from the post-boost dataset. Participants with a breakthrough infection pre-third dose were excluded. Samples after fourth doses of the vaccine or breakthrough infections were censored. Participants without a minimum of two valid time points at least 14 days post-dose 3 were excluded.

845 Antibody decay has been observed in interventional settings where external antibody 846 treatments were administered. Unlike clinical treatments, natural immunity has multiple sources of 847 antibody production. Since there are multiple sources of antibody production naturally within the 848 body, single component exponential decay models are insufficient as they will over-predict the 849 change in decay rates. The model used here has two components which are assumed to have 850 distinct decay rates. When reporting aggregate antibody data, the geometric mean is generally 851 used due to a high variability within and among participants (across multiple orders of magnitudes 852 in the datasets used here). By fitting the model directly within the log-transformed space, the output 853 curve directly estimates the geometric mean rather than the arithmetic mean.

$$\log_2 AUC = \log_2 \left(e^{a + r_1} e^{\frac{-b}{100}(days - 14)} + e^{c + r_2} \right)$$

854

855 All models were generated using the NLMIXED procedure in SAS9.4. This procedure is 856 capable of fitting arbitrary nonlinear functions including both fixed and random effects. The specific 857 model structure used in this case is shown in **Supplemental Figure 3B**. A two-phase fitting 858 procedure was used. First, a simplified model without random effects was run from a naïve starting 859 point, and the fitted parameter values were used as the initial values for the mixed effects model. In 860 order to account for underlying variability across participants that was not captured by the fixed 861 effects, a random effect was added to each component for the final mixed effect model. In addition 862 to allowing for variability in the overall magnitude of the antibody response, this approach captures 863 observed variability in the kinetics of the response (fold-reduction relative to peak varies among 864 participants). The model was fit independently to datasets for participants with and without pre-865 vaccine SARS-CoV-2 infection (hybrid immunity) using a feature in SAS to build stratified models. 866 The same model framework was used for both post-vaccine and post-boost models. Data from a 867 post-boost model fit to the combined dataset without accounting for pre-vaccine immune status is 868 also presented, reflecting a close correspondence in post-boost kinetics in both stratified groups.

869 The impact of demographic factors was assessed in the stratified post-vaccine and post-870 boost models. In all cases, these factors were assessed as a multiplicative factor across the entire 871 time course studied (manifesting on graphs with log-transformed y axes as a y shift). All 872 demographically informed models were constructed iteratively, beginning with a model including all 873 factors considered (age, gender, race, ethnicity, and primary vaccine type). After each model fitting 874 run, the factor with the highest assessed p value was removed if that p value did not meet a 875 relaxed threshold for statistical significance (p < 0.1). The model was then re-run with the reduced 876 set of fixed effects and finalized when all factors hit this relaxed threshold. This stepwise 877 subtractive modeling practice helps to account for confounding factors and avoids double 878 controlling for effects that alter the result through the same mechanism. Results from the model

- 879 fitting in SAS were exported to csvs for visualization in Python. SAS code for the model fitting will
- 880 be made available in a public GitHub repository.

881 SUPPLEMENTAL TABLES

882

883 Supplemental Table 1: Model development and validations

Model	Hybrid Im munity	Par am e te r	Transformed Value	Transforme d C I Lower Bound	Transformed CI Upper Bound	Transformed Units	Es ti ma te	Stan dar dE rr or	DF	tValue	Probt	Alph a	Lower	Upper	Gradient
Vaccine:Stratified	no	a (short-lived component)	5746.81	5 176.06	6381.13	AUC	8.6564	0.05311	231	16 2 .9 8	< 0 0 0 1	0.05	8.5518	8.7611	1.8E-07
		b (de cayrate)	29.60	31.23	28.13	Half-Life days	2.3421	0.06208	231	37.73	< 0 0 0 1	0.05	2.2 198	2.4644	-1.4E-08
		c (stabl e componen t)	327.63	288.88	371.59	AUC	5.7919	0.06391	231	90.63	< 0 0 0 1	0.05	5.666	5.9178	1.8E-08
		s1 vari an ce	0.32	0.29	0.35		0.3177	0.01411	231		<.0001	0.05	0.2899	0.3455	
		r1 vari an ce	0.35	0.27	0.44		0.3535	0.04412	231		<.0001	0.05	0.2666	0.4404	
		r2 variance	0.69	0.53	0.84		0.6853	0.07699	231		<.0001	0.05	0.5336	0.837	
-		r1_r2 covariance	0.27	0.19 13244.00	0.36	[N/A]	0.2715	0.04387	231 124		<.0001 <.0001	0.05	0.1851 9.4913	0.358	-8E-07 4.24E-09
	ye s	a (short-lived component) b (de cayrate)	15427.59 30.74	15244.00 33.46		Half-Life days	2.2546	0.07708	12.4		< 0.001	0.05	2.0714	2.4379	4.24E-09 -4.5E-10
		c (stable component)	1776.68	1503.42	20.45		7.4825	0.09238	12.4		< 0 0 0 1	0.05	7.3 155	7.6495	-4.5E-10
		s1 variance	0.26	0.23	0.29		0.2562	0.01454	12.4		<.0001	0.05	0.2274	0.285	
		r1 variance	0.49	0.33		IN/A	0.4878	0.07744	12.4		< 0 0 0 1	0.05	0.3345	0.6411	
		r2 variance	0.76	0.55	0.97	IN/A	0.759	0.1053	12.4	7.21	<.0001	0.05	0.5507	0.9674	
		r1_r2 covariance	0.49	0.34	0.64	IN/A	0.4929	0.07584	12.4	6.5	< 0 0 0 1	0.05	0.3428	0.6431	-2 .5 E -0 8
Boost: Stratified	no	a (short-lived component)	7540.92	6502.23	8744.67	AUC	8.9281	0.07493	14 1	119.16	< 0 0 0 1	0.05	8.7799	9.0762	-7.2E-09
		b (de cayrate)	44.34	50.34	39.62	Half-Life d ays	1.5633	0.09424	14 1	16.59	< 0 0 0 1	0.05	1.377	1.7 496	-1.2E-10
		c (stable component)	1960.20	1523.70	2521.98		7.5808	0.1274	14 1		< 0 0 0 1	0.05	7.3289	7.8328	
		s1 vari an ce	0.30	0.26		IN/A	0.2963	0.01692	14 1		<.0001	0.05	0.2628	0.3297	
		r1 vari an ce	0.33	0.22		IN/A	0.33	0.05706	141		<.0001	0.05	0.2 172	0.4428	
		r2 variance	1.41	0.98		IN /A	1.40 83	0.2176	141		<.0001	0.05	0.9781	1.8385	
ŀ	ye s	r1_r2 covariance a (short-lived component)	0.11 5442.53	-0.08 4339.44	6826.04	IN/A	0.1106	0.09835	141 78		0.2629	0.05	-0.08389 8.3755	0.305	
	yes	b (de cay rate)	72.79	4555.44		Half-Life days	0.9523	0.1138	78		<.0001	0.05	0.7472	1.1574	
		c (stable component)	196 1.3 7	1408.81	2730.66		7.5814	0.1662	78		< 0 0 0 1	0.05	7.2505	7.9 12 3	
		s1 variance	0.2.2	0.18		[N/A]	0.2154		78		<.0001	0.05	0.1823	0.2485	
		r1 vari ance	0.59	0.29		IN/A	0.5872	0.1488	78		0.0002	0.05	0.291	0.8834	
		r2 variance	0.73	0.36	1.10	[N/A]	0.73 19	0.1852	78	3.95	0.0002	0.05	0.3632	1.1006	-2.2E-07
		r1_r2 covariance	0.06	-0.20	0.33	IN/A	0.06411	0.1329	78	0.48	0.6309	0.05	-0.2005	0.3287	1.25E-07
Boost: Un stratifie d	N/A	a (short-lived component)	1.6 5	1.15		AUC	8.8 15		221		<.0001	0.05	8.6917	8.9383	
		b (de cayrate)	7.84	8.01		Half-Life d ays	1.4392	0.07482	221		<.0001	0.05	1.2917	1.5866	-2 E - 0 9
		c (stabl e componen t)	4.67	3.88		AUC	7.6625	0.09389	221		<.0001	0.05	7.4774	7.8475	
		s1 vari an ce	7.48	7.21		IN/A	0.2731		221		<.0001	0.05	0.2483	0.298	
		r1 vari an ce	0.30	0.26		[N/A]	0.4229	0.07467	221		<.0001	0.05	0.2757	0.57	
		r2 variance r1 r2 covariance	0.08	-0.18		IN/A IN/A	1.122	0.1457	221		<.0001 0.1111	0.05	0.8347	1.4092	2.39E-09 2.91E-09
Vaccine +	no	a (short-lived component)	8 15 9 .19	6032.40	11036.91		9.0069	0.06726	221		< 0.001	0.05	8.7049	9.309	2.91E-09 1.63E-07
Demographics:	10	b (de cayrate)	29.61	31.24		Half-Life days	2.341	0.06187	231		<.0001	0.05	2.2 19 1	2.4629	-4.1E-09
Stratified	1	c (stable component)	463.91	341.62	630.05		6.1397	0.1553	231		< 0 0 0 1	0.05	5.8337	6.4458	
		s1 vari ance	0.32	0.29	0.35	[N/A]	0.3179	0.01416	231		< 0 0 0 1	0.05	0.29	0.3458	
		r1 vari an ce	0.32	0.24		IN/A	0.3181	0.04102	231	7.75	<.0001	0.05	0.2372	0.3989	4.63E-08
		r2 variance	0.62	0.48	0.76	IN/A	0.6219	0.07097	231	8.76	< 0 0 0 1	0.05	0.482	0.7617	6.47E-08
		r1_r2 covarian ce	0.23	0.15	0.31	[N/A]	0.2283	0.04018	231		<.0001	0.05	0.1491	0.3075	-3.5E-07
		beta (age)	-0.02	-0.02		Log2 Fold-Change	-0 .0 15 42		231		0.0016	0.05	-0.02495	-0.00589	0.00002
		be ta (primary vaccine type)	0.52	0.26		Log2 Fold-Change	0.5155	0.1286	231		<.0001	0.05	0.2621	0.7689	
	ye s	a (short-lived component)	10 13 9 .5 6	6071.74	16932.67		9.22.42	0.2591	12 4		<.0001	0.05	8.7114	9.737	
		b (de cayrate)	30.67	33.39		Half-Life days	2.26	0.09286	12.4		< 0 0 0 1	0.05	2.0762	2.4438	-1.2 E-08
		c (stable component) s1 variance	1167.36 0.26	696.10 0.23	1957.45 0.29		7.0625	0.2612	12 4 12 4		< 0 0 0 1 < 0 0 0 1	0.05	6.5455 0.2278	7.5794	
		r1 variance	0.46	0.23	0.60		0.2387	0.07416	12.4		< 0 0 0 1	0.05	0.2278	0.2836	5.2E-07
		r2 variance	0.75	0.54	0.96	1.7.1	0.754	0.1065	12.4		<.0001	0.05	0.5433	0.9647	
		r1 r2 covariance	0.48	0.33		IN/A	0.4791	0.07378	12.4		< 0 0 0 1	0.05	0.333	0.6251	
		beta (age)	0.01	0.00		Log2 Fold-Change	0.01218		12.4		0.1386	0.05	-0.00399	0.02836	
		be ta (primary vaccine type)	0.34	-0.11		Log2 Fold-Change	0.3433	0.2279	12.4		0.1344	0.05	-0.1077	0.7943	6.51E-09
Boost +	no	a (short-lived component)	6878.80	5722.15	8269.26		8.8362	0.093 12	14 1		< 0 0 0 1	0.05	8.6521	9.0203	
Demographics:		b (de cayrate)	44.96	51.12		Half-Life d ays	1.5417	0.09406	14 1		< 0001	0.05	1.3558	1.7277	-8.4E-08
Stratified		c (stabl e componen t)	1769.05	1354.11	2311.38		7.4782	0.1352	14 1		< 0 0 0 1	0.05	7.2 109	7.7456	-1.8E-07
		s1 vari an ce	0.30	0.26		IN/A	0.2964	0.01679	14 1		<.0001	0.05	0.2632	0.3295	-6 .5 E -0
		r1 vari an ce	0.32	0.24		IN/A	0.3225	0.04249	14 1		<.0001	0.05	0.2385	0.4065	
		r2 variance	1.38	0.93		[N /A]	1.3827	0.229	141		< 0.00 1	0.05	0.93	1.8354	2.46-0
		r1_r2 covariance	0.08	-0.18		IN/A	0.07543	0.1294	141		0.5610	0.05	-0.1804	0.3313	-4.8E-07
ŀ		be ta (primary vaccine type)	0.50	0.14		Log2 Fold-Change	0.5009	0.1818	141		0.0067	0.05	0.1414	0.8604	
	ye s	a (short-lived component)	5480.22		6986.26		8.6089 0.9521	0.122	78		< 0.001		8.3661	8.8517	4.62E-0
		b (de cayrate)	72.80 1975.15	92.75 1404.03	59.91 2778.59	Half-Life days	0.9521	0.1029	78 78		<.0001	0.05	0.7473 7.2471	1.1569 7.9297	-8E-0
		c (stable component) s1 variance	1975.15	1404.03		IN/A	0.2155	0.1714	78		<.0001	0.05	0.1824	0.2486	2.3E-0
		r1 variance	0.22	0.18		[N/A]	0.2155	0.01662	78		0.0002	0.05	0.1824	0.2486	
		r2 variance	0.55	0.25		[N/A]	0.7307	0.1479	78		0.0002	0.05	0.2928	1.0997	-3.2E-0
		r1_r2 covariance	0.06	-0.20		IN/A	0.06488	0.13 15	78		0.6232	0.05	-0.1969	0.3267	
		i i i i i i i i i i i i i i i i i i i	0.00	-0.20	0.00	The second se	0.00400	0.1010	, 0		0.8748	0.00	0.2000	0.0207	4.46.690

884

885

887 Supplemental Table 2: Overview of the immune histories (infection, vaccination) for the 228

888 PARIS participants who completed all three vaccine reactogenicity surveys.

889 890

Infection Group	Vaccination Series	Male	Female	Unknown	Total
Naïve	Pfizer	26	73	1	100
<i>N: 14</i> 9	Moderna	12	24	1	37
Hybrid Immunity (Pre-Vaccine Infection)	Heterogenous Pfizer	6 15	5 27	1 1	12 43
N: 63 Breakthrough	Moderna Heterogenous Pfizer	1 5 1	7 7 9	0 0 0	8 12 10
Infection	Moderna	0	1	0	1
<i>N: 11</i>	Heterogenous	0	0	0	0
Pre-Vaccine and Breakthrough Infection <i>N: 5</i>	Pfizer Moderna	1 0	3 1	0	4 1
	Heterogenous	0	0	0	0
	Totals	67	157	4	228

891

893 Supplemental Table 3: Vaccine side effects divided by vaccine doses and immunity


894 groups

	Serostatus k	y Vaccine Type	е		Total by Vac	cine Type	Total by Serostatus			
	Naïve (N=16	50)	Hybrid Imm	unity (N=68)	Total (N=22	В)	Total (N=228)			
	Moderna	Pfizer	Moderna	Pfizer	Moderna	Pfizer	Naïve	Hybrid Immunity		
	N=42 (26%)	N=118 (74%)	N=15 (22%)	N=53 (78%)	N=57 (25%)	N=171 (75%)	N=160 (70%)	N=68 (30%)		
Local Symptoms										
Pain	33 (79%)	86 (73%)	14 (93%)	41 (77%)	47 (82%)	127 (74%)	119 (74%)	55 (81%)		
Erythema	7 (17%)	14 (12%)	3 (20%)	5 (9%)	10 (18%)	19 (11%)	21 (13%)	8 (12%)		
Induration	11 (26%)	17 (14%)	7 (47%)	7 (13%)	18 (32%)	24 (14%)	28 (18%)	14 (21%)		
Lymphadenopathy	4 (10%)	23 (19%)	1 (7%)	4 (8%)	5 (8%)	27 (16%)	27 (17%)	5 (7%)		
Other	1 (2%)	6 (5%)	4 (27%)	1 (2%)	5 (8%)	7 (4%)	7 (4%)	5 (7%)		
Any Local	33 (79%)	90 (76%)	14 (93%)	42 (79%)	47 (82%)	132 (77%)	123 (77%)	56 (82%)		
Systemic Symptoms										
Fatigue	24 (57%)	80 (68%)	13 (87%)	31 (58%)	37 (65%)	111 (65%)	104 (65%)	44 (65%)		
Headache	27 (64%)	56 (47%)	9 (60%)	28 (53%)	36 (63%)	81 (47%)	83 (52%)	34 (50%)		
Myalgia	19 (45%)	56 (47%)	10 (67%)	32 (60%)	29 (51%)	77 (45%)	75 (47%)	31 (46%)		
Chills	17 (40%)	43 (36%)	11 (73%)	20 (38%)	28 (49%)	63 (37%)	60 (37%)	31 (46%)		
Arthralgia	14 (33%)	19 (16%)	7 (47%)	7 (13%)	21 (37%)	26 (15%)	33 (21%)	14 (21%)		
Fever	19 (45%)	36 (31%)	9 (60%)	11 (21%)	28 (49%)	47 (27%)	55 (34%)	20 (29%)		
Nausea/Emesis	7 (17%)	11 (9%)	2 (13%)	7 (13%)	9 (16%)	18 (11%)	54 (34%)	36 (53%)		
Pharyngitis	4 (10%)	11 (9%)	1 (7%)	3 (6%)	5 (8%)	14 (8%)	15 (9%)	4 (6%)		
Other	6 (14%)	5 (4%)	0 (0%)	3 (6%)	6 (11%)	8 (5%)	11 (7%)	3 (4%)		
Any Systemic	33 (79%)	88 (74%)	13 (87%)	40 (75%)	46 (81%)	128 (75%)	121 (76%)	53 (78%)		

897 SUPPLEMENTAL FIGURES

898

Srivastava et al., Supplemental Fig. 1



899

900


901 Supplemental Figure S1:

A: Study visits from each of the 496 PARIS participants are shown colored by year of study followup. A total of 8,041 samples were collected over the three years of the study.

B: Flow chart illustrating the data selection from PARIS study participants for the specific analyses
 performed. Figures in which a given dataset or subset thereof are shown are listed. Datasets
 based on infection data are shown in dark orange.

907

Srivastava et al., Supplemental Fig. 2



910 Supplemental Figure S2: Antibody kinetics after vaccination.

911 Early timepoints post-vaccine. Participants with hybrid immunity due to pre-vaccine SARS-CoV-2

912 infection are shown in orange, and those without are shown in blue. Participants with breakthrough


913 infections are excluded. Lines connect geometric means for 5-day bins (10-day bins post-dose 4),

914 with confidence intervals constructed by bootstrapping.

915 A: Longitudinal antibody data collected within 40 days after vaccination. Data from participants 916 with (124 participants, 375 samples) and without (166 participants, 528 samples) pre-existing 917 immunity are shown. Approximate peak timepoints for each group are indicated by dashed lines.

- 918 B: Longitudinal antibody data collected within 40 days after the third vaccine dose. Data for 919 participants with (59 participants, 151 samples) and without (157 participants, 448 samples) prior 920 SARS-CoV-2 infection.
- C: Longitudinal antibody data collected within 40 days after the 4th vaccine for participants with (12 921
- participants, 28 samples) and without (25 participants, 57 samples) prior SARS-CoV-2 infection 922
- 923

Srivastava et al., Supplemental Fig. 3



924

925 Supplemental Figure S3: PARIS model development.

A: The three parameters of the vaccine are illustrated here, with 'c' representing the "steady-state"
 antibody level, 'a' representing the magnitude of the fast-decaying component, and 'b' representing
 the rate of that decay.

929 B: Comparison of a linear fit (grey) and the PARIS model fit (black) to the first five months of data

930 for one representative study participant, with extrapolation from each model plotted against


additional timepoints censored from model training.

vaccine series

SARS-CoV-2 infection prior to primary

Srivastava et al., Supplemental Fig. 4

No SARS-CoV-2 infection prior to primary vaccine series



932 Supplemental Figure S4: Frequency of mild, moderate and severe side effects reported after
 933 SARS-CoV-2 vaccine doses 1, 2 and 3.

934 Local and systemic side effects were recorded after the first (A), second (B) and third vaccine (C) 935 doses in PARIS participants with (right, yellow) and without (left, blue) pre-existing immunity. 230 936 participants completed all three surveys. Symptom severity was self-reported and classified as 937 mild, moderate, or severe based on description and duration.